A composition comprising or consisting of L-theanine and one or more fructooligosaccharides, wherein the ratio of L-theanine to froctooligosaccharide(s) is of about 2:1 to 99:1. A composition in the form of a food or nutraceutical, and also in the form of a powder, granules, suspension, tablet, capsule, lozenge, bakery item, sweets, drink, beverage or oral preparation.

The disclosure provides microbial compositions (e.g., compositions comprising one or more microbes or protein components thereof), that can be administered to subjects to confer beneficial effects. Disclosed compositions can, for example, be useful in reducing visceral hypersensitivity, or pain in response to colorectal distension.

The present disclosure relates generally to formulations, compositions or foodstuff additives for use in modulating a glycemic response for treating or preventing diabetes or obesity and processes and method of its manufacture. Described is a formulation, a composition or a foodstuff for modulating a glycemic response manufactured from at least one phenylpropanoid encapsulated in a first cyclodextrin; and a second cyclodextrin. Preferably, the at least one phenylpropanoid is quercetin, phlorizin, myricetin, dihydromyricetin or any combination thereof, the first cyclodextrin is gamma cyclodextrin, and the second cyclodextrin is alpha cyclodextrin.

The present disclosure relates generally to formulations, compositions or foodstuff additives for use in modulating a glycemic response for treating or preventing diabetes or obesity and processes and method of its manufacture. Described is a formulation, a composition or a foodstuff for modulating a glycemic response manufactured from at least one phenylpropanoid encapsulated in a first cyclodextrin; and a second cyclodextrin. Preferably, the at least one phenylpropanoid is quercetin, phlorizin, myricetin, dihydromyricetin or any combination thereof, the first cyclodextrin is gamma cyclodextrin, and the second cyclodextrin is alpha cyclodextrin.

A dietary composition and method for treating kidney damage and/or disease with a fasting-mimicking diet is provided. The method includes a step of identifying a subject having kidney damage. A low sodium fasting-mimicking diet with a specific dietary composition is administered to the subject for a first time period of 1 to 10 days.

A dietary composition and method for treating kidney damage and/or disease with a fasting-mimicking diet is provided. The method includes a step of identifying a subject having kidney damage. A low sodium fasting-mimicking diet with a specific dietary composition is administered to the subject for a first time period of 1 to 10 days.

In one aspect, thermal energy storage compositions are described herein. In some embodiments, a composition comprises 0.5-10 wt. % polysaccharide and 88-99.5 wt. % water, wherein the weight percentages are based on the total weight of the composition. Moreover, in some cases, the composition is shape stable at 20° C. and 1 atm.

In one aspect, thermal energy storage compositions are described herein. In some embodiments, a composition comprises 0.5-10 wt. % polysaccharide and 88-99.5 wt. % water, wherein the weight percentages are based on the total weight of the composition. Moreover, in some cases, the composition is shape stable at 20° C. and 1 atm.

The present invention relates to compositions for use in treating or preventing mastitis, for example sub-clinical mastitis, in a subject. In particular, the invention relates to a diet and /or nutritional composition which are characterised by a low inflammatory potential for their use in in treating or preventing mastitis, in particular sub-clinical mastitis, in lactating women. The present invention also relates to a risk prediction tool for the occurrence of subclinical mastitis in lactating women, which is based on the inflammatory potential of their diets.

The present invention relates to compositions for use in treating or preventing mastitis, for example sub-clinical mastitis, in a subject. In particular, the invention relates to a diet and /or nutritional composition which are characterised by a low inflammatory potential for their use in in treating or preventing mastitis, in particular sub-clinical mastitis, in lactating women. The present invention also relates to a risk prediction tool for the occurrence of subclinical mastitis in lactating women, which is based on the inflammatory potential of their diets.